105 results about "Receptor antibody" patented technology

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Provided herein are chimeric cytokine receptors bearing a binding domain capable of binding a TGF-β ligand or a TGF-β receptor antibody. When present on chimeric antigen receptor (CAR)-bearing immune cells (CAR-T-cells), such receptors allow for increased CAR-T cell expansion, activity and persistence, constitutively and / or through engagement of a TGF-β ligand or a TGF-β receptor antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The present invention relates to a fluorescent detection kit for detecting hydroxocobalamin receptor antibodies in central nervous system vitamin B12 deficiency and its application, which can efficiently and accurately detect the presence and concentration of anti-CD320 antibodies in patient serum or cerebrospinal fluid. The kit uses a specific antibody to bind to the CD320 protein produced by cells expressing the CD320 gene, which then binds to a fluorescently labeled secondary antibody to generate a fluorescent signal, thereby diagnosing central nervous system vitamin B12 deficiency. The base sequence in this application ensures the effective expression of the CD320 gene, which is crucial for improving the sensitivity and specificity of the test.

Pharmaceutical compositions of anti-TSLP-R antibodies and uses thereof are provided herein. Pharmaceutical compositions can include, for example, an anti-TSLP-R antibody, or an antigen-binding fragment thereof, pharmaceutically acceptable buffers, excipients, and surfactants, or other compositions as provided herein.

The present invention relates to anti-chemokine-like receptor 1 antibodies and therapeutic uses thereof. The present invention provides anti-CMKLR1 compounds having agonist ability for the interaction between Resolvin E1 and CMKLR1, and their use in the treatment or prevention of diseases, particularly diseases in which inflammation regression is delayed or disrupted.

This invention relates to a novel use of IL-1β-ligand / IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and / or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and / or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and / or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some cases, the antibodies are cross-reactive with one or more non-human animal uPAR polypeptides, such as non-human primate uPAR, e.g., cynomolgus monkey uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins, and conjugates of the present disclosure to treat conditions associated with uPAR expression and / or activity are also provided. In some embodiments, the condition associated with uPAR expression and / or activity is cancer. Non-limiting examples of such cancers include cancers characterized by cancer cells expressing uPAR on their surface, cancers characterized by stromal cells within the tumor microenvironment expressing uPAR on their surface, and the like.

The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers.

This invention provides an antibody that binds to the Frizzled receptor, particularly an antibody that binds to the Frizzled receptor 4-cysteine-rich domain, and a method for using the same. [Solution] The present invention provides an isolated antibody and immunoconjugate that specifically bind to the Frizzled receptor (FZD) 4 cysteine-rich domain (CRD), comprising a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises complementarity-determining regions CDR-H1, CDR-H2, and CDR-H3, and the light chain variable region comprises complementarity-determining regions CDR-L1, CDR-L2, and CDR-L3, and the amino acid sequence of the CDR comprises or consists of a sequence selected from a specific group of sequences.

Provided is a heterohybridoma-based method of generating recombinant rabbit monoclonal antibodies, recombinant anti-IL-6 receptor-alpha (IL-6Rα) antibodies generated using such methods, and immune assay methods kits employing such antibodies.

The present invention relates to methods of reducing occurrence or severity of dermatologic adverse events (DAEs) in a subject treated with an anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody and EGFR tyrosine kinase inhibitor, comprising (a) administering an antibiotic(s); (b) administering an antiseptic(s); and (c) administering a non-comedogenic moisturizer to the subject.

Provided herein are an antibody or antigen binding fragment that specifically recognizes and / or binds to an anti-interleukin 6 receptor. The antibodies or antigen binding fragments provided by the present disclosure have biological activity, FcRn affinity and antibody stability, and have prospects for clinical application.

Interleukin-23 receptor (IL23R) VHH antibodies are disclosed, as well as methods of making and using the same, e.g., for treatment of IL23-mediated diseases and disorders, including, e.g., gastrointestinal-related (Gl-related) diseases (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)), a colon cancer, a small intestine cancer, a gastric cancer, an irritable bowel syndrome, a gastrointestinal ulcer, a gut-associated infection (e.g., a Salmonella infection or a Clostridium difficile infection), celiac disease, or pathogenic inflammation).

To provide a new method for treating lupus nephritis (LN), which improves renal response, reduces recurrence, prevents eventual end-stage renal disease (ESRD), and reduces the need for glucocorticoids.SOLUTION: WHAT IS CLAIMED IS: 1. A method of reducing lupus nephritis (LN) disease activity in a subject in need thereof, comprising administering to the subject a type I IFN receptor (IFNAR1) inhibiting agent. Preferably, the IFNAR1 inhibitors are human monoclonal antibodies specific for IFNAR1, such as anifrolumab.SELECTED DRAWING: None

The present invention provides caninized mouse antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.

To provide an improved therapy capable of addressing one or more symptoms of atopic dermatitis.SOLUTION: The present invention provides an antibody to canine IL-4 receptor α that has a high binding affinity for canine IL-4 receptor α and can block the binding of canine IL-4 and / or IL-13 to canine IL-4 receptor α. The present invention further relates to epitopes of canine IL-4 receptor α that bind to the antibody to canine IL-4 receptor α. The present invention further provides the use of the antibody for the treatment of atopic dermatitis in dogs.SELECTED DRAWING: Figure 1

The present application relates to an activin receptor II antibody and a use. The activin receptor II antibody comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3. A mutation relative to CDRs of a parental antibody includes one or more selected from the following: a heavy chain CDR2 V54A mutation, a heavy chain CDR2 G56L mutation, a heavy chain CDR2 T58K mutation, a heavy chain CDR3 G99S mutation, a heavy chain CDR3 G99T mutation, a light chain CDR1 G24H mutation, a light chain CDR1 D28W mutation, a light chain CDR1 Y32F mutation, a light chain CDR2 P57E mutation, a light chain CDR3 S97A mutation, and a light chain CDR3 Y99N mutation. A balanced activin receptor II dual-blocking antibody that exhibits higher affinity for ActRIIA while not significantly reducing affinity for ActRIIB is obtained by screening.

The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.

Provided are a novel determination method, diagnostic probe, and diagnostic kit for inflammatory bowel disease. A method for determining inflammatory bowel disease includes measuring an anti-endothelial cell protein C receptor antibody (anti-EPCR antibody) in a sample collected from a subject.

The invention belongs to the technical field of biological medicine, and relates to a recombinant NMDA receptor antibody and application thereof. The invention relates to a recombinant NMDA receptor antibody Tat-DiN2B and application of the recombinant NMDA receptor antibody Tat-DiN2B in preparation of a medicine for inhibiting neurological function defect. The nerve injury which can be inhibited by the Tat-DiN2B comprises cortical neuron excitatory toxicity injury, acute hippocampal brain slice excitatory toxicity injury and cerebral ischemia injury. Meanwhile, the Tat-DiN2B can also be used for improving the dyskinesia and anxiety level after cerebral ischemia. The Tat-DiN2B disclosed by the invention is constructed by taking a gene synthesized by Tat and DiN2B as a template through the steps of PCR (Polymerase Chain Reaction) amplification, enzyme digestion, transformation, transfection, expression, purification and the like, and a DNA (Deoxyribonucleic Acid) sequence of the Tat-DiN2B is as shown in SEQ ID No.1.

All currently available treatment options for muscular dystrophy such as Duchenne muscular dystrophy (DMD) carry substantial potential safety risks. Further, no approved therapies exist for DMD that specifically target progressive bone loss and recurrent fragility fractures. The invention provides a means for a treatment for muscular dystrophy, such as DMD, and its related diseases or disorders, comprising an IL-6 inhibitor such as anti-IL-6 receptor antibody or antigen binding fragment thereof.

To provide a stable anti-OSMR antibody formulation.SOLUTION: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0 to 7.6, where less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.SELECTED DRAWING: None

The present disclosure relates to the use of an anti-IL6 receptor antibody or antigen-binding fragment thereof for the treatment of polymyalgia rheumatic (PMR).

Recent studies indicate that sIL7R is involved in the development of autoimmune diseases. The present invention provides methods and compositions for a novel antibody therapeutic against the soluble isoform of the interleukin 7 receptor (sIL7R), a potent driver of self-destructive immune responses that cause autoimmune diseases including multiple sclerosis, lupus nephritis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, and many other autoimmune diseases. The present invention includes antibodies specific for sIL7R that inhibit SIL7R, a driver of autoimmunity, without inhibiting mIL7R, thereby reducing the severity of or preventing autoimmunity without activating immunosuppressive mechanisms.

The present invention provides therapeutic agents for treating human asthma through administration of an IL-6 inhibitor to humans. Representative IL-6 inhibitors in the present invention include IL-6 receptor antibodies and IL-6 antibodies. Therapeutic agents of the present invention can yield therapeutic effects in severe asthma patients who need administration of high-dose steroids and such for alleviation of symptoms, or even in patients whose symptoms are difficult to control by common treatment.

The present disclosure provides humanized anti-GluN1 receptor antibodies and antigen-binding fragments or derivatives thereof, which are effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D- aspartate (NMDA) receptors, as well as pharmaceutical compositions and medical uses thereof, particularly for the treatment of neurological, neurovascular or neurodegenerative disorders, such as stroke, multiple sclerosis, Parkinson' s disease, and others.

The present invention relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and a GLP-1 agonist molecule, such as a GLP-1 agonist peptide. Such constructs are useful in the treatment of numerous diseases and disorders, including metabolic disorders such as obesity, diabetes, and others.

Provided herein are antigen binding proteins that specifically bind to interleukin-4 receptor (IL4R), their compositions and methods of use. Also provided herein are methods of using the IL4R antigen binding proteins for treatment of allergic or inflammatory diseases.